Total Product Life-Cycle Analysis and Costing

1997 ◽  
Author(s):  
Nabil Nasr ◽  
Edward A. Varel
Author(s):  
David E. Lee ◽  
Michel A. Melkanoff

Abstract Traditional engineering analysis of product designs has focused primarily on a product’s operational performance without considering costs of manufacturing and other stages downstream from design. In contrast, life cycle analysis of a product during its initial development can play a crucial role in determining the product’s overall life cycle cost and useful life span. This paper examines product life cycle engineering analysis - measurement of product operational performance in a life cycle context. Life cycle engineering analysis is thus considered both as an extension of traditional engineering analysis methods and as a subset of a total product life cycle analysis. The issues critical to life cycle engineering analysis are defined and include product life cycle data modeling and analysis, analysis tools and their performance regimes, performance tradeoff measurement and problems of life cycle engineering analysis in an organizational context. Recommendations are provided for future research directions into life cycle engineering analysis in the context of integration architectures for concurrent engineering.


2021 ◽  
Vol 8 ◽  
Author(s):  
Staci J. Kearney ◽  
Amanda Lowe ◽  
Jochen K. Lennerz ◽  
Anil Parwani ◽  
Marilyn M. Bui ◽  
...  

Manufacturers of pathology imaging devices and associated software engage regulatory affairs and clinical affairs (RACA) throughout the Total Product Life Cycle (TPLC) of regulated products. A number of manufacturers, pathologists, and end users are not familiar with how RACA involvement benefits each stage of the TPLC. RACA professionals are important contributors to product development and deployment strategies because these professionals maintain an understanding of the scientific, technical, and clinical aspects of biomedical product regulation, as well as the relevant knowledge of regulatory requirements, policies, and market trends for both local and global regulations and standards. Defining a regulatory and clinical strategy at the beginning of product design enables early evaluation of risks and provides assurance that the collected evidence supports the product's clinical claims (e.g., in a marketing application), its safe and effective use, and potential reimbursement strategies. It is recommended to involve RACA early and throughout the TPLC to assist with navigating changes in the regulatory environment and dynamic diagnostic market. Here we outline how various stakeholders can utilize RACA to navigate the nuanced landscape behind the development and use of clinical diagnostic products. Collectively, this work emphasizes the critical importance of RACA as an integral part of product development and, thereby, sustained innovation.


1981 ◽  
Vol 45 (4) ◽  
pp. 60-67 ◽  
Author(s):  
George S. Day

Each of the articles in this special section makes a distinctive contribution to the long-standing controversy over the managerial value of the product life cycle concept. This overview is designed to put these articles into a broader perspective by analyzing the major issues of identification, forecasting, and strategy formulation encountered in any meaningful application of the product life cycle.


1988 ◽  
Vol 5 (1-2) ◽  
pp. 117-132
Author(s):  
Arvin F. Rodrigues ◽  
T.R. Thiaga Rajan ◽  
Norman Kangun

2004 ◽  
Vol 6 (6) ◽  
pp. 761-766 ◽  
Author(s):  
Ethan D. Hausman ◽  
Sousan S. Altaie

Sign in / Sign up

Export Citation Format

Share Document